Top

Published in:

01-06-2011 | Research

Expression of Thyroid Transcription Factor-1 in Malignant Pleural Effusions

Authors: Andras Khoor, Angela L. Byrd-Gloster, Santo V. Nicosia

Published in: Pathology & Oncology Research | Issue 2/2011

Abstract

Separating adenocarcinoma of the lung from non-pulmonary adenocarcinoma or malignant mesothelioma is difficult, especially in cytology specimens. Consequently, it is important to identify markers that may facilitate this distinction. Thyroid transcription factor-1 (TTF-1) is a homeodomain containing transcription factor expressed selectively in the thyroid, lung, and diencephalon. TTF-1 is also expressed in adenocarcinomas of the lung and is widely used as a pulmonary adenocarcinoma marker in surgical specimens. However, the utility of TTF-1 has rarely been investigated in cytology. In this study, we evaluated the expression of TTF-1 in malignant pleural effusions. The primary tumors included 26 pulmonary adenocarcinomas, 26 non-pulmonary adenocarcinomas (13 breast, 5 ovarian, 2 gastric, 2 prostatic, 1 esophageal, 1 colonic, 1 pancreatic and 1 renal) and 4 malignant mesotheliomas. Immunocytochemistry was performed on sections of cell blocks, using a mouse monoclonal TTF-1 antibody (clone 8G7G3/1) and a biotin-streptavidin detection system. Nuclear immunoreactivity for TTF-1 was detected in 19 pulmonary adenocarcinomas. All non-pulmonary adenocarcinomas and malignant mesotheliomas were negative. These data indicate that TTF-1 maintains its sensitivity (73%) and specificity (100%) in cell block preparations and is useful in separating adenocarcinoma of the lung from non-pulmonary adenocarcinoma and malignant mesothelioma in cytology specimens.

Johnston WW (1985) The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 56:905–909PubMedCrossRef

Monte SA, Ehya H, Lang WR (1987) Positive effusion cytology as the initial presentation of malignancy. Acta Cytol 31:448–452PubMed

Attanoos RL, Gibbs AR (2003) ‘Pseudomesotheliomatous’ carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group Cardiff. Histopathology 43:444–452PubMedCrossRef

Lazzaro D, Price M, de Felice M, Di Lauro R (1991) The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development 113:1093–1104PubMed

Stahlman MT, Gray ME, Whitsett JA (1996) Expression of thyroid transcription factor-1(TTF-1) in fetal and neonatal human lung. J Histochem Cytochem 44:673–678PubMedCrossRef

Whitsett JA, Glasser SW (1998) Regulation of surfactant protein gene transcription. Biochim Biophys Acta 1408:303–311PubMed

Maeda Y, Dave V, Whitsett JA (2007) Transcriptional control of lung morphogenesis. Physiol Rev 87:219–244PubMedCrossRef

Katoh R, Kawaoi A, Miyagi E et al (2000) Thyroid transcription factor-1 in normal, hyperplastic, and neoplastic follicular thyroid cells examined by immunohistochemistry and nonradioactive in situ hybridization. Mod Pathol 13:570–576PubMedCrossRef

Katoh R, Miyagi E, Nakamura N et al (2000) Expression of thyroid transcription factor-1 (TTF-1) in human C cells and medullary thyroid carcinomas. Hum Pathol 31:386–393PubMedCrossRef

10.

Burke LM, Rush WI, Khoor A et al (1999) Alveolar adenoma: a histochemical, immunohistochemical, and ultrastructural analysis of 17 cases. Hum Pathol 30:158–167PubMedCrossRef

11.

Devouassoux-Shisheboran M, Hayashi T, Linnoila RI et al (2000) A clinicopathologic study of 100 cases of pulmonary sclerosing hemangioma with immunohistochemical studies: TTF-1 is expressed in both round and surface cells, suggesting an origin from primitive respiratory epithelium. Am J Surg Pathol 24:906–916PubMedCrossRef

12.

Holzinger A, Dingle S, Bejarano PA et al (1996) Monoclonal antibody to thyroid transcription factor-1: production, characterization, and usefulness in tumor diagnosis. Hybridoma 15:49–53PubMedCrossRef

13.

Khoor A, Whitsett JA, Stahlman MT et al (1999) Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 30:695–700PubMedCrossRef

14.

Folpe AL, Gown AM, Lamps LW et al (1999) Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 12:5–8PubMed

15.

Byrd-Gloster AL, Khoor A, Glass LF et al (2000) Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. Hum Pathol 31:58–62PubMedCrossRef

16.

Bejarano PA, Baughman RP, Biddinger PW et al (1996) Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 9:445–452PubMed

17.

Moldvay J, Jackel M, Bogos K et al (2004) The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res 10:85–88PubMedCrossRef

18.

Strickland-Marmol LB, Khoor A, Livingston SK, Rojiani A (2007) Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain. Arch Pathol Lab Med 131:1686–1690PubMed

19.

Afify AM, al-Khafaji BM (2002) Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. Acta Cytol 46:675–678PubMedCrossRef

20.

Hecht JL, Pinkus JL, Weinstein LJ, Pinkus GS (2001) The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. Am J Clin Pathol 116:483–488PubMedCrossRef

21.

Ng WK, Chow JC, Ng PK (2002) Thyroid transcription factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion fluid cytology specimens. Cancer 96:43–48PubMedCrossRef

22.

Yang GC, Wan LS, Papellas J, Waisman J (1998) Compact cell blocks. Use for body fluids, fine needle aspirations and endometrial brush biopsies. Acta Cytol 42:703–706PubMed

23.

Armitage P, Berry G, Matthews JNS (2002) Statistical Methods in Medical Research, Fourth edth edn. Blackwell Science, OxfordCrossRef

24.

Colby TV (2004) Adenocarcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds) Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC, Lyon, pp 35–44

25.

Khoor A, Gray ME, Hull WM et al (1993) Developmental expression of SP-A and SP-A mRNA in the proximal and distal respiratory epithelium in the human fetus and newborn. J Histochem Cytochem 41:1311–1319PubMedCrossRef

26.

Khoor A, Gray ME, Singh G, Stahlman MT (1996) Ontogeny of Clara cell-specific protein and its mRNA: their association with neuroepithelial bodies in human fetal lung and in bronchopulmonary dysplasia. J Histochem Cytochem 44:1429–1438PubMedCrossRef

27.

Khoor A, Stahlman MT, Gray ME, Whitsett JA (1994) Temporal-spatial distribution of SP-B and SP-C proteins and mRNAs in developing respiratory epithelium of human lung. J Histochem Cytochem 42:1187–1199PubMedCrossRef

28.

Khoor A, Whitsett JA, Stahlman MT et al (1997) Immunoreactivity for thyroid transcription factor-1 (TTF-1) correlates with better prognosis in early stage adenocarcinoma of the lung. Am J Respir Crit Care Med 155:A36, Abstract

29.

Puglisi F, Barbone F, Damante G et al (1999) Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. Mod Pathol 12:318–324PubMed

30.

Tan D, Li Q, Deeb G et al (2003) Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 34:597–604PubMedCrossRef

31.

Weir BA, Woo MS, Getz G et al (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450:893–898PubMedCrossRef

32.

Kwei KA, Kim YH, Girard L et al (2008) Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27:3635–3640PubMedCrossRef

33.

Di Loreto C, Puglisi F, Di Lauro V et al (1998) TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Lett 124:73–78PubMedCrossRef

34.

Pelosi G, Fraggetta F, Pasini F et al (2001) Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol 25:363–372PubMedCrossRef

35.

Ordonez NG (2003) The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 27:1031–1051PubMedCrossRef

36.

Motoi N, Szoke J, Riely GJ et al (2008) Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 32:810–827PubMedCrossRef

37.

Tsuta K, Ishii G, Nitadori J et al (2006) Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol 209:78–87PubMedCrossRef

38.

Kubba LA, McCluggage WG, Liu J et al (2008) Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol 21:485–490PubMedCrossRef

39.

Zhang PJ, Gao HG, Pasha TL et al (2009) TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol 28:10–18PubMedCrossRef

Title: Expression of Thyroid Transcription Factor-1 in Malignant Pleural Effusions
Authors: Andras Khoor
Angela L. Byrd-Gloster
Santo V. Nicosia
Publication date: 01-06-2011
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-010-9308-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Implication of RAF and RKIP Genes in Urinary Bladder Cancer

PET-CT Imaging and Reality

Intestinal Langerhans Cell Histiocytosis-like Lesion in an Adult Presented with Diverticulitis: A Reactive or Neoplastic Condition?

Expression and Clinical Significance of FAK and Src Proteins in Human Endometrial Adenocarcinoma

PHOSPHO-STAT5 Expression is Associated with Poor Prognosis of Human Colonic Adenocarcinoma

Activation of the PI3K/Akt Pathway Mediates Bone Morphogenetic Protein 2-Induced Invasion of Pancreatic Cancer Cells Panc-1

Keynote webinar | Spotlight on antibody–drug conjugates in cancer